Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lensar Inc (NQ: LNSR )

5.380 -0.300 (-5.28%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Lensar Inc

< Previous 1 2 Next >
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From LENSAR, Inc.
Via Business Wire
LENSAR to Participate in Two Upcoming Investor Conferences
From LENSAR, Inc.
Via Business Wire
LENSAR Reports Second Quarter 2024 Results and Provides Business Update
From LENSAR, Inc.
Via Business Wire
LENSAR Announces Certification for the ALLY® Adaptive Cataract Treatment System in the European Union
From LENSAR, Inc.
Via Business Wire
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From LENSAR, Inc.
Via Business Wire
LENSAR to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
From LENSAR, Inc.
Via Business Wire
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From LENSAR, Inc.
Via Business Wire
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From LENSAR, Inc.
Via Business Wire
LENSAR to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference
From LENSAR, Inc.
Via Business Wire
LENSAR Reports First Quarter 2024 Results and Provides Business Update
From LENSAR, Inc.
Via Business Wire
LENSAR to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
From LENSAR, Inc.
Via Business Wire
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From LENSAR, Inc.
Via Business Wire
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From LENSAR, Inc.
Via Business Wire
LENSAR Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
From LENSAR, Inc.
Via Business Wire
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From LENSAR, Inc.
Via Business Wire
LENSAR to Report Fourth Quarter and Full Year 2023 Financial Results on Monday, March 4, 2024
From LENSAR, Inc.
Via Business Wire
LENSAR Reports Third Quarter 2023 Results and Provides Business Update
From LENSAR, Inc.
Via Business Wire
LENSAR to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
From LENSAR, Inc.
Via Business Wire
LENSAR Reports Second Quarter 2023 Results and Provides Business Update
From LENSAR, Inc.
Via Business Wire
LENSAR® Reports Adoption of ALLY® System in Multi-Center Ophthalmology Groups
From LENSAR, Inc.
Via Business Wire
LENSAR Reports First Quarter 2023 Results and Provides Business Update
From LENSAR, Inc.
Via Business Wire
LENSAR to Report First Quarter 2023 Financial Results on Monday, May 15, 2023
From LENSAR, Inc.
Via Business Wire
LENSAR Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update
From LENSAR, Inc.
Via Business Wire
LENSAR to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023
From LENSAR, Inc.
Via Business Wire
LENSAR Announces Preliminary Fourth Quarter and Full Year 2022 Results
From LENSAR, Inc.
Via Business Wire
LENSAR to Present at Two Upcoming Investor Conferences
From LENSAR, Inc.
Via Business Wire
LENSAR Reports Third Quarter 2022 Financial Results and Provides Business Update
From LENSAR, Inc.
Via Business Wire
LENSAR to Report Third Quarter 2022 Financial Results on Wednesday, November 9, 2022
From LENSAR, Inc.
Via Business Wire
LENSAR Announces Application for Certification of the ALLY™ Adaptive Cataract Treatment System in the EU
From LENSAR, Inc.
Via Business Wire
First Patients Treated with LENSAR’s® ALLY™ Adaptive Cataract Treatment System
From LENSAR, Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.